Cancers, Free Full-Text

After forty years of essentially unchanged treatment in acute myeloid leukemia (AML), innovation over the past five years has been rapid, with nine drug approvals from 2016 to 2021. Increased understanding of the molecular changes and genetic ontology of disease have led to targeting mutations in isocitrate dehydrogenase, FMS-like tyrosine kinase 3 (FLT3), B-cell lymphoma 2 and hedgehog pathways. Yet outcomes remain variable; especially in defined molecular and genetic subgroups such as NPM1 (Nucleophosmin 1) mutations, 11q23/KMT2A rearranged and TP53 mutations. Emerging therapies seek to address these unmet needs, and all three of these subgroups have promising new therapeutic approaches. Here, we will discuss the normal biological roles of menin in acute leukemia, notably in KMT2A translocations and NPM1 mutation, as well as current drug development. We will also explore how CD47 inhibition may move immunotherapy into front-line settings and unlock new treatment strategies in TP53 mutated disease. We will then consider how these new therapeutic advances may change the management of AML overall.

O Amar Mota Bou Get File - Colaboratory

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer

from Flow Cytometry to Cytomics, Page 2

PDF) Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment

Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease - eBioMedicine

ROS in cancer therapy: the bright side of the moon

The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study - eClinicalMedicine

Pan-cancer whole-genome comparison of primary and metastatic solid tumours

Epigenetic regulation during cancer transitions across 11 tumour types

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study - The Lancet Oncology

Destination Healthy Skin Toolkit - The Skin Cancer Foundation

Concordance among Gene-Expression–Based Predictors for Breast Cancer

Cancers, Free Full-Text

Cancer Free Posters for Sale